---
title: "Darzalex (daratumumab) in multiple myeloma: Dosing and administration questions"
description: "Dosing and administration questions on Darzalex (daratumumab) in multiple myeloma, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: IV vs subcutaneous, Dosing, Premedication, and Administration. Questions: What is the difference between Darzalex IV and Darzalex Faspro? How long does a Darzalex infusion or Darzalex Faspro injection take? Is Darzalex Faspro as effective as Darzalex IV (COLUMBA)? Can patients switch from Darzalex IV to Darzalex Faspro? 14 further questions follow. 18 questions quoted from 5 sources."
canonical: "https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/dosing-and-administration"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Darzalex (daratumumab) in multiple myeloma: Dosing and administration questions

Manufacturer: Janssen Biotech, Inc.  
Prescribing information: [Darzalex](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf), [Darzalex Faspro](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf)

Questions that apply to every indication of Darzalex are on [Darzalex (daratumumab), all indications](https://www.evicenter.com/medical-information/darzalex).

## IV vs subcutaneous

<a id="darzalex-iv-vs-subcutaneous"></a>

### What is the difference between Darzalex IV and Darzalex Faspro?

> “DARZALEX FASPRO<sup>®</sup> is administered as a subcutaneous injection over 
> ~3 to 5 minutes while DARZALEX<sup>®</sup> is given as an intravenous infusion 
> over 7 hours for the first infusion, 4 hours for the second infusion, and  
> 3 hours for subsequent infusions (median).<sup>1,2</sup>”

Source: [DARZALEX: DARZALEX FASPRO®, page 3, captured 2026-11-12](https://www.darzalexhcp.com/pdfs/dosing-and-administration-guide-faspro.pdf#page=3)

> “~3 to 5 minute subcutaneous injection administered  
> by a healthcare provider
> Fixed dose; no weight-based calculations
> Single-dose vial, no dilution needed
> Same dosing schedules as DARZALEX<sup>®</sup> (daratumumab)  
> for approved indications*
> *Split first dose option for DARZALEX<sup>®</sup> is not applicable to DARZALEX FASPRO<sup>®</sup>.”

Source: [DARZALEX: DARZALEX FASPRO®, page 3, captured 2026-11-12](https://www.darzalexhcp.com/pdfs/dosing-and-administration-guide-faspro.pdf#page=3)

> “The recommended dose of DARZALEX FASPRO is 1,800 mg/30,000 units 
> (1,800 mg daratumumab and 30,000 units hyaluronidase) administered 
> subcutaneously over approximately 3 to 5 minutes.”

Source: [DARZALEX: DARZALEX FASPRO®, page 2, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=2)

> “The recommended dose of DARZALEX is 16 mg/kg actual body weight 
> administered as an intravenous infusion according to the following dosing 
> schedule:”

Source: [DARZALEX: DARZALEX®, page 2, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=2)

Note: The first two passages are from the Dosing and Administration Guide that the Darzalex HCP site links; the last two are from the DARZALEX FASPRO and DARZALEX Prescribing Information.

<a id="darzalex-administration-time"></a>

### How long does a Darzalex infusion or Darzalex Faspro injection take?

> “DARZALEX FASPRO<sup>®</sup> is administered subcutaneously over ~3 to 5 minutes while DARZALEX<sup>®</sup> is given intravenously over 7 hours for the first infusion, 4 hours for the second infusion, and 3 hours for subsequent infusions (median).<sup>1,2</sup>”

Source: [DARZALEX: DRd Dosing, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/dosing/#:~:text=is%20administered%20subcutaneously%20over%20~3,3%20hours%20for%20subsequent%20infusions)

> “The recommended dose of DARZALEX FASPRO is 1,800 mg/30,000 units 
> (1,800 mg daratumumab and 30,000 units hyaluronidase) administered 
> subcutaneously over approximately 3 to 5 minutes.”

Source: [DARZALEX: DARZALEX FASPRO®, page 2, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=2)

> “Median durations of 16 mg/kg infusions for the Week 1, Week 2, 
> and subsequent infusions were approximately 7, 4, and 3 hours respectively.”

Source: [DARZALEX: DARZALEX®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=4)

<a id="darzalex-columba-subcutaneous-vs-iv"></a>

### Is Darzalex Faspro as effective as Darzalex IV (COLUMBA)?

Applies to: Relapsed or refractory multiple myeloma after at least 3 prior lines: DARZALEX FASPRO vs intravenous DARZALEX monotherapy (COLUMBA)

> “The efficacy of DARZALEX  FASPRO as monotherapy was evaluated in 
> COLUMBA (NCT03277105), an open-label, randomized, non-inferiority study. 
> Eligible patients were required to have relapsed or refractory multiple myeloma 
> who had received at least 3 prior lines of therapy including a proteasome 
> inhibitor and an immunomodulatory agent or who were double-refractory 
> to a proteasome inhibitor and an immunomodulatory agent. Patients were 
> randomized to receive DARZALEX FASPRO 1,800 mg/30,000 units administered 
> subcutaneously or daratumumab 16 mg/kg administered intravenously; each 
> administered once weekly from weeks 1 to 8, once every 2 weeks from weeks 
> 9 to 24 and once every 4 weeks starting with week 25 until unacceptable 
> toxicity or disease progression. The major efficacy outcome measures were 
> ORR by the IMWG response criteria and maximum Ctrough at pre-dose Cycle 3 
> Day 1 [see Clinical Pharmacology (12.3)]. Randomization was stratified by body 
> weight, myeloma type, and number of prior lines of therapy.
> A total of 522 patients were randomized: 263 to the DARZALEX FASPRO arm 
> and 259 to the intravenous daratumumab arm. The median age was 67 years 
> (range: 33 to 92 years); 55% were male; and 78% were White, 14% Asian, 
> and 3% Black or African American. The median weight was 73 kg (range: 29 
> to 138). Patients had received a median of 4 prior lines of therapy. A total of 
> 51% of patients had a prior ASCT; 100% of patients received both a PI and an 
> immunomodulatory agent. Forty-nine percent of patients were refractory both 
> a PI and an immunomodulatory agent. Eighty-two percent of patients were 
> refractory to their last line of prior systemic therapy.”

Source: [DARZALEX: DARZALEX FASPRO®, page 17, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=17)

> “The results show that DARZALEX FASPRO 1,800 mg/30,000 units administered 
> subcutaneously is non-inferior to daratumumab 16 mg/kg administered 
> intravenously in terms of ORR and maximum trough concentration [see Clinical 
> Pharmacology (12.3)]. Median progression-free survival was 5.6 months in the 
> DARZALEX FASPRO arm and 6.1 months in the intravenous daratumumab arm. 
> ORR results are provided in Table 34.
> Table 34: Efficacy Results from COLUMBA
> DARZALEX 
> FASPRO  
> (N=263)
> Intravenous 
> Daratumumab  
> (N=259)
> Overall response (sCR+CR+VGPR+PR), n (%)<sup>a</sup>
> 108 (41%)
> 96 (37%)
> 95% CI (%)
> (35%, 47%)
> (31%, 43%)
> Ratio of response rates (95% CI)
> 1.11 (0.89, 1.37)
> CR or better, n (%)
> 5 (1.9%)
> 7 (2.7%)
> Very good partial response (VGPR)
> 45 (17%)
> 37 (14%)
> Partial response (PR)
> 58 (22%)
> 52 (20%)
> <sup>a</sup>	 Based on intent-to-treat population.”

Source: [DARZALEX: DARZALEX FASPRO®, page 18, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=18)

Note: COLUMBA enrolled patients with relapsed or refractory multiple myeloma. Table 34 columns are DARZALEX FASPRO (N=263) and intravenous daratumumab (N=259), in that order.

<a id="darzalex-switch-iv-to-subcutaneous"></a>

### Can patients switch from Darzalex IV to Darzalex Faspro?

> “DARZALEX FASPRO<sup>®</sup> makes subcutaneous injection possible, starting 
> with the first dose. DARZALEX<sup>®</sup> patients can also be switched to 
> DARZALEX FASPRO<sup>®</sup> at any point in approved DARZALEX FASPRO<sup>®</sup> 
> indications only.<sup>1,4</sup>”

Source: [DARZALEX: DARZALEX FASPRO®, page 30, captured 2026-11-12](https://www.darzalexhcp.com/pdfs/dosing-and-administration-guide-faspro.pdf#page=30)

Note: This statement is from the Dosing and Administration Guide that the Darzalex HCP site links.

## Dosing

<a id="darzalex-smoldering-treatment-duration"></a>

### How long is Darzalex Faspro given for high-risk smoldering multiple myeloma?

Applies to: High-risk smoldering multiple myeloma: DARZALEX FASPRO monotherapy vs active monitoring (AQUILA)

> “2.3	 Recommended Dosage for High-Risk Smoldering Multiple Myeloma
> The recommended dose of DARZALEX FASPRO is 1,800 mg/30,000 units 
> (1,800 mg daratumumab and 30,000 units hyaluronidase) administered 
> subcutaneously over approximately 3 to 5 minutes.
> Use the dosing schedule provided in Table 7 when DARZALEX FASPRO is 
> administered as monotherapy in high-risk smoldering multiple myeloma 
> patients (4-week cycle).
> Table 7: DARZALEX FASPRO dosing schedule for monotherapy (4-week cycle)
> Weeks
> Schedule
> Weeks 1 to 8
> weekly (total of 8 doses)
> Weeks 9 to 24<sup>a</sup>
> every two weeks (total of 8 doses)
> Week 25 onwards until diagnosis of 
> multiple myeloma or a maximum of 
> 3 years<sup>b</sup>
> every four weeks
> <sup>a</sup>	 First dose of the every-2-week dosing schedule is given at Week 9
> <sup>b</sup>	 First dose of the every-4-week dosing schedule is given at Week 25”

Source: [DARZALEX: DARZALEX FASPRO®, page 3, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=3)

<a id="darzalex-faspro-dose"></a>

### What is the dose of Darzalex Faspro?

> “2.1	 Important Dosing Information
> •	 DARZALEX FASPRO is for subcutaneous use only.
> •	 Administer medications before and after administration of 
> DARZALEX  FASPRO to minimize administration-related reactions 
> [see Dosage and Administration (2.6)].
> •	 Type and screen patients prior to starting DARZALEX FASPRO.
> 2.2	 Recommended Dosage for Multiple Myeloma
> The recommended dose of DARZALEX FASPRO is 1,800 mg/30,000 units 
> (1,800 mg daratumumab and 30,000 units hyaluronidase) administered 
> subcutaneously over approximately 3 to 5 minutes. Tables 1, 2, 3, 4, 5, and 6 
> provide the recommended dosing schedule when DARZALEX FASPRO is 
> administered as monotherapy or as part of a combination therapy.”

Source: [DARZALEX: DARZALEX FASPRO®, page 2, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=2)

> “Injection: 1,800 mg daratumumab and 30,000 units hyaluronidase per 15 mL 
> (120 mg and 2,000 units/mL) colorless to yellow and clear to opalescent 
> solution in a single-dose vial.”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

<a id="darzalex-iv-dose-split-first-dose"></a>

### What is the dose of Darzalex IV?

> “The recommended dose of DARZALEX is 16 mg/kg actual body weight 
> administered as an intravenous infusion according to the following dosing 
> schedule:”

Source: [DARZALEX: DARZALEX®, page 2, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=2)

<a id="darzalex-split-first-infusion"></a>

### Can the first Darzalex infusion be split over two days?

> “The recommended dose of 16 mg/kg to be administered on Day 1 when 
> DARZALEX is administered as monotherapy or in combination may be split 
> over two consecutive days, such that an 8 mg/kg dose is administered on 
> Day 1 and Day 2, respectively.”

Source: [DARZALEX: DARZALEX®, page 3, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=3)

> “<sup>‡</sup>The option of splitting the first dose for DARZALEX<sup>®</sup> is not applicable to DARZALEX FASPRO<sup>®</sup>.<sup>1,2</sup>”

Source: [DARZALEX: DRd Dosing, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/dosing/#:~:text=option%20of%20splitting%20the%20first,is%20not%20applicable%20to%20DARZALEX)

<a id="darzalex-drd-dosing-schedule"></a>

### What is the Darzalex dosing schedule with lenalidomide and dexamethasone (DRd)?

Applies to: Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX + lenalidomide + dexamethasone (DRd) vs Rd (MAIA)

> “Starting at Cycle 7 (~6 months), patients will transition to approximately once-monthly dosing for DARZALEX FASPRO<sup>®</sup> or DARZALEX<sup>®</sup> + Rd”

Source: [DARZALEX: DRd Dosing, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/dosing/#:~:text=Starting%20at%20Cycle%207%20%28~6,Rd)

> “Continue DRd until disease progression or unacceptable toxicity”

Source: [DARZALEX: DRd Dosing, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/dosing/#:~:text=Continue%20DRd%20until%20disease%20progression%20or%20unacceptable%20toxicity)

> “DARZALEX FASPRO<sup>®</sup> in combination with lenalidomide and dexamethasone (4-week cycle) has the same dosing schedule as DARZALEX<sup>®</sup> in combination with lenalidomide and dexamethasone.<sup>1,2‡</sup>”

Source: [DARZALEX: DRd Dosing, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/dosing/#:~:text=or%20unacceptable%20toxicity-,DARZALEX,in%20combination%20with%20lenalidomide%20and)

> “First dose of the every-2-week dosing schedule is given at Week 9. First dose of the every-4-week dosing schedule is given at Week 25.<sup>1,2</sup>”

Source: [DARZALEX: DRd Dosing, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/dosing/#:~:text=First%20dose%20of%20the%20every%2D2%2Dweek,every%2D4%2Dweek%20dosing%20schedule%20is%20given%20at%20Week)

> “<sup>†</sup>Cycle=28 days.”

Source: [DARZALEX: DRd Dosing, captured 2026-11-12](https://www.darzalexhcp.com/triplet/maia/dosing/#:~:text=days.)

> “Table 1: DARZALEX Dosing Schedule in Combination With Lenalidomide 
> or Pomalidomide (4-Week Cycle) and Low-Dose Dexamethasone 
> and for Monotherapy
> Weeks
> Schedule
> Weeks 1 to 8
> weekly (total of 8 doses)
> Weeks 9 to 24<sup>a</sup>
> every two weeks (total of 8 doses)
> Week 25 onwards until disease 
> progression<sup>b</sup>
> every four weeks
> <sup>a</sup>	 First dose of the every-2-week dosing schedule is given at Week 9
> <sup>b</sup>	 First dose of the every-4-week dosing schedule is given at Week 25”

Source: [DARZALEX: DARZALEX®, page 2, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=2)

> “Lenalidomide (25 mg once daily 
> orally on Days 1-21 of repeated 28-day [4-week] cycles) was given with low 
> dose oral or intravenous dexamethasone 40 mg/week (or a reduced dose 
> of 20 mg/week for patients >75 years or body mass index [BMI] <18.5). On 
> DARZALEX infusion days, the dexamethasone dose was given as a pre-infusion 
> medication.”

Source: [DARZALEX: DARZALEX®, page 11, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=11)

<a id="darzalex-dvrd-transplant-ineligible-schedule"></a>

### What is the Darzalex Faspro dosing schedule with VRd for transplant-ineligible patients?

Applies to: Newly diagnosed multiple myeloma, ineligible for autologous stem cell transplant: DARZALEX FASPRO + bortezomib, lenalidomide, dexamethasone (DVRd) vs VRd (CEPHEUS)

> “Use the dosing schedule in Table 5 when DARZALEX FASPRO is administered 
> in combination with bortezomib, lenalidomide, and dexamethasone (3-week 
> cycle) for treatment of newly diagnosed multiple myeloma patients who are 
> ineligible for ASCT.
> Table 5: DARZALEX FASPRO dosing schedule in combination with 
> bortezomib, lenalidomide and dexamethasone (3-week cycle)
> Weeks
> Schedule
> Weeks 1 to 6
> weekly (total of 6 doses)
> Weeks 7 to 24<sup>a</sup>
> every three weeks (total of 6 doses)
> Week 25 onwards until disease 
> progression<sup>b</sup>
> every four weeks
> <sup>a</sup>	 First dose of the every-3-week dosing schedule is given at Week 7
> <sup>b</sup>	 First dose of the every-4-week dosing schedule is given at Week 25
> When DARZALEX FASPRO is administered as part of a combination therapy, 
> see Clinical Studies (14.1) and the prescribing information for dosage 
> recommendations for the other drugs.”

Source: [DARZALEX: DARZALEX FASPRO®, page 3, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=3)

> “Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered 
> subcutaneously once weekly from weeks 1 to 6, once every three weeks from 
> weeks 7 to 24, and once every 4 weeks starting with week 25 until disease 
> progression or unacceptable toxicity. Bortezomib was administered by 
> subcutaneous injection at a dose of 1.3 mg/m<sup>2</sup> body surface area twice weekly 
> (days 1, 4, 8, and 11) in repeated 21-day (3-week) cycles from Cycles 1-8. 
> Lenalidomide was administered orally at 25 mg daily on Days 1-14 of Cycles 1-8 
> and on Days 1-21 during Cycles 9 and beyond. Dexamethasone was administered 
> orally at 20 mg on Days 1, 2, 4, 5, 8, 9, 11, and 12 of Cycles 1-8 (or at 20 mg 
> on Days 1, 4, 8, and 11 for patients >75 years or BMI <18.5) and at 40 mg on 
> Days 1, 8, 15, and 22 during Cycles 9 and beyond (or at a reduced dose of 20 mg 
> per week for patients >75 years or BMI <18.5). On the days of DARZALEX FASPRO 
> injection, the dexamethasone dose was administered orally or intravenously 
> as a pre-injection medication.”

Source: [DARZALEX: DARZALEX FASPRO®, page 15, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=15)

> “Continue DVRd until disease progression or unacceptable toxicity”

Source: [DARZALEX: CEPHEUS DVRd Dosing, captured 2026-11-12](https://www.darzalexhcp.com/quad/cepheus/dosing/#:~:text=Continue%20DVRd%20until%20disease%20progression%20or%20unacceptable%20toxicity)

<a id="darzalex-dvrd-transplant-eligible-schedule"></a>

### What is the Darzalex Faspro dosing schedule with VRd for transplant-eligible patients?

Applies to: Newly diagnosed multiple myeloma, eligible for autologous stem cell transplant: DARZALEX FASPRO + VRd induction and consolidation vs VRd (PERSEUS)

> “Use the dosing schedule in Table 4 when DARZALEX FASPRO is administered in 
> combination with bortezomib, lenalidomide, and dexamethasone (4-week cycle) 
> for treatment of newly diagnosed multiple myeloma patients eligible for ASCT.
> Table 4: DARZALEX FASPRO dosing schedule in combination with 
> bortezomib, lenalidomide and dexamethasone (4-week cycle)
> Treatment phase
> Weeks
> Schedule
> Induction
> Weeks 1 to 8
> weekly (total of 8 doses)
> Weeks 9 to 16<sup>a</sup>
> every two weeks (total of 4 doses)
> Stop for high dose chemotherapy and ASCT
> Consolidation
> Weeks 1 to 8<sup>b</sup>
> every two weeks (total of 4 doses)
> ª	 First dose of the every-2-week dosing schedule is given at Week 9
> <sup>b</sup>	 First dose of the every-2-week dosing schedule is given at Week 1 upon 
> re-initiation of treatment following ASCT
> When DARZALEX FASPRO is administered as part of a combination therapy, 
> see Clinical Studies (14.1) and the prescribing information for dosage 
> recommendations for the other drugs.”

Source: [DARZALEX: DARZALEX FASPRO®, page 3, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=3)

> “Patients received DARZALEX FASPRO 1,800 mg/30,000 units administered 
> subcutaneously once weekly from weeks 1 to 8 and once every 2 weeks from 
> weeks 9 to 16 during induction. After week 16, patients underwent stem cell 
> mobilization, high dose chemotherapy, and ASCT. Within 12 weeks of ASCT, 
> and when engraftment was complete, patients received DARZALEX FASPRO 
> once every 2 weeks from weeks 1 to 8 during consolidation. Bortezomib was 
> administered by subcutaneous injection at a dose of 1.3 mg/m<sup>2</sup> body surface 
> area twice weekly for two weeks (days 1, 4, 8, and 11) of each 28-day cycle for 
> weeks 1-16 during induction and weeks 1-8 during consolidation. Lenalidomide 
> was administered orally at 25 mg daily (days 1-21) during weeks 1-16 during 
> induction and weeks 1-8 during consolidation. Dexamethasone (oral or 
> intravenous) was administered at 40 mg on Days 1-4 and Days 9-12 during 
> weeks 1-16 during induction and weeks 1-8 during consolidation. On the days 
> of DARZALEX FASPRO injection, the dexamethasone dose was administered 
> orally or intravenously as a pre-injection medication.”

Source: [DARZALEX: DARZALEX FASPRO®, page 15, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=15)

<a id="darzalex-missed-dose"></a>

### What if a Darzalex or Darzalex Faspro dose is missed?

> “2.5	 Missed DARZALEX FASPRO Doses
> If a dose of DARZALEX FASPRO is missed, administer the dose as soon as 
> possible and adjust the dosing schedule to maintain the dosing interval.”

Source: [DARZALEX: DARZALEX FASPRO®, page 3, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=3)

> “Missed DARZALEX Doses
> If a dose of DARZALEX is missed, administer the dose as soon as possible and 
> adjust the dosing schedule to maintain the dosing interval.”

Source: [DARZALEX: DARZALEX®, page 3, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=3)

## Premedication

<a id="darzalex-faspro-premedication"></a>

### What premedications and post-medications are given with Darzalex Faspro?

> “Administer the following pre-medications 1 to 3 hours before each dose of 
> DARZALEX FASPRO:
> •	 Acetaminophen 650 mg to 1,000 mg orally
> •	 Diphenhydramine 25 mg to 50 mg (or equivalent) orally or intravenously
> •	 Corticosteroid (long- or intermediate-acting)
> Monotherapy
> Administer methylprednisolone 100 mg (or equivalent) orally or 
> intravenously. Consider reducing the dose of methylprednisolone to 
> 60 mg (or equivalent) following the second dose of DARZALEX FASPRO.
> In Combination
> Administer dexamethasone 20 mg (or equivalent) orally or intravenously 
> prior to every DARZALEX FASPRO administration.
> When dexamethasone is the background regimen-specific corticosteroid, 
> the dexamethasone dose that is part of the background regimen will 
> serve as pre-medication on DARZALEX FASPRO administration days 
> [see Clinical Studies (14)].
> Do not administer background regimen-specific corticosteroids (e.g., 
> prednisone) on DARZALEX FASPRO administration days when patients 
> have received dexamethasone (or equivalent) as a pre-medication.
> Post-medication
> Administer the following post-medications:
> Monotherapy
> Administer methylprednisolone 20 mg (or an equivalent dose of an 
> intermediate- or long-acting corticosteroid) orally for 2 days starting 
> the day after the administration of DARZALEX FASPRO.
> In Combination
> Consider administering oral methylprednisolone at a dose of less than or 
> equal to 20 mg (or an equivalent dose of an intermediate- or long-acting 
> corticosteroid) on the day after administration of DARZALEX FASPRO.
> If a background regimen-specific corticosteroid (e.g., dexamethasone, 
> prednisone) is administered the day after the administration of 
> DARZALEX FASPRO, additional corticosteroids may not be needed 
> [see Clinical Studies (14)].”

Source: [DARZALEX: DARZALEX FASPRO®, page 3, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=3)

> “If the patient does not experience a major systemic administration-related 
> reaction after the first 3 doses of DARZALEX FASPRO, consider discontinuing 
> the administration of corticosteroids (excluding any background regimen-
> specific corticosteroid).
> For patients with a history of chronic obstructive pulmonary disease, consider 
> prescribing short and long-acting bronchodilators and inhaled corticosteroids. 
> Following the first 4 doses of DARZALEX FASPRO, consider discontinuing 
> these additional post-medications, if the patient does not experience a major 
> systemic administration-related reaction.”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

<a id="darzalex-iv-premedication"></a>

### What premedications are required before a Darzalex IV infusion?

> “Administer the following pre-infusion medications 1 hour to 3 hours before 
> every DARZALEX infusion:
> •	 Corticosteroid (long- or intermediate-acting)
> Monotherapy:
> Administer methylprednisolone 100 mg (or equivalent) intravenously. 
> Following the second infusion, consider reducing the dose to 60 mg (or 
> equivalent) administered either orally or intravenously.
> In Combination:
> Administer dexamethasone 20 mg (or equivalent) orally or intravenously.
> When dexamethasone is the background regimen-specific corticosteroid, 
> the dexamethasone dose that is part of the background regimen will serve 
> as pre-medication on DARZALEX infusion days [see Clinical Studies (14)].
> Do not administer background regimen-specific corticosteroids (e.g. 
> prednisone) on DARZALEX infusion days when patients have received 
> dexamethasone (or equivalent) as a pre-medication.
> •	 Acetaminophen 650 mg to 1,000 mg orally
> •	 Diphenhydramine 25 mg to 50 mg (or equivalent) orally or intravenously.
> Post-infusion Medication
> Administer the following post-infusion medications:
> Monotherapy:
> Administer methylprednisolone 20  mg (or an equivalent dose of an 
> intermediate- or long-acting corticosteroid) orally for 2 days starting the 
> day after the administration of DARZALEX.
> In Combination:
> Consider administering oral methylprednisolone at a dose of less than or 
> equal to 20 mg (or an equivalent dose of an intermediate- or long-acting 
> corticosteroid) beginning the day after the administration of a DARZALEX 
> infusion.
> If a background regimen-specific corticosteroid (e.g. dexamethasone, 
> prednisone) is administered the day after the DARZALEX infusion, 
> additional corticosteroids may not be needed [see Clinical Studies (14)].
> For patients with a history of chronic obstructive pulmonary disease, consider 
> prescribing short and long-acting bronchodilators and inhaled corticosteroids. 
> Following the first 4 DARZALEX infusions, consider discontinuing these 
> additional post-infusion medications, if the patient does not experience a 
> major infusion-related reaction.”

Source: [DARZALEX: DARZALEX®, page 3, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=3)

<a id="darzalex-herpes-zoster-prophylaxis"></a>

### Does Darzalex or Darzalex Faspro require shingles (herpes zoster) prophylaxis?

> “Initiate antiviral prophylaxis to prevent herpes zoster reactivation within 
> 1 week after starting DARZALEX FASPRO and continue for 3 months following 
> the end of treatment [see Adverse Reactions (6.1)].”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

> “Initiate antiviral prophylaxis to prevent herpes zoster reactivation within 
> 1 week after starting DARZALEX and continue for 3 months following the end 
> of treatment [see Adverse Reactions (6.1)].”

Source: [DARZALEX: DARZALEX®, page 3, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=3)

## Administration

<a id="darzalex-iv-infusion-rates"></a>

### What are the Darzalex IV infusion rates?

> “Administer DARZALEX intravenously at the infusion rate described below 
> in Table 6. Consider incremental escalation of the infusion rate only in the 
> absence of infusion-related reactions.”

Source: [DARZALEX: DARZALEX®, page 3, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=3)

> “Table 6: Infusion Rates for DARZALEX (16 mg/kg) Administration
> Dilution 
> volume
> Initial rate 
> (first hour)
> Rate 
> increment<sup>a</sup>
> Maximum 
> rate
> Week 1 Infusion
> Option 1  
> (Single dose infusion)
> Week 1 Day 1  
> (16 mg/kg)
> 1,000 mL
> 50 mL/hour
> 50 mL/hour 
> every hour
> 200 mL/hour
> Option 2  
> (Split dose infusion)
> Week 1 Day 1  
> (8 mg/kg)
> 500 mL
> 50 mL/hour
> 50 mL/hour 
> every hour
> 200 mL/hour
> Week 1 Day 2  
> (8 mg/kg) 
> 500 mL
> 50 mL/hour
> 50 mL/hour 
> every hour
> 200 mL/hour
> Week 2 (16 mg/kg)<sup>b</sup>
> 500 mL
> 50 mL/hour
> 50 mL/hour 
> every hour
> 200 mL/hour
> Week 3 onwards  
> (16 mg/kg)<sup>c</sup>
> 500 mL
> 100 mL/hour
> 50 mL/hour 
> every hour
> 200 mL/hour
> <sup>a</sup>	 Consider incremental escalation of the infusion rate only in the absence 
> of infusion-related reactions.
> <sup>b</sup>	 Use a dilution volume of 500 mL for the 16 mg/kg dose only if there were 
> no infusion-related reactions the previous week. Otherwise, use a dilution 
> volume of 1,000 mL.
> <sup>c</sup>	 Use a modified initial rate (100 mL/hour) for subsequent infusions (i.e. 
> Week 3 onwards) only if there were no infusion-related reactions during 
> the previous infusion. Otherwise, continue to use instructions indicated in 
> the table for the Week 2 infusion rate.”

Source: [DARZALEX: DARZALEX®, page 3, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX-pi.pdf#page=3)

Note: Table 6 columns are dilution volume, initial rate (first hour), rate increment, and maximum rate.

<a id="darzalex-faspro-injection"></a>

### How is Darzalex Faspro injected?

> “DARZALEX FASPRO should be administered by a healthcare provider.
> To prevent medication errors, check the vial labels to ensure that the drug 
> being prepared and administered is DARZALEX FASPRO for subcutaneous 
> use. Do not administer DARZALEX FASPRO intravenously.
> DARZALEX FASPRO is ready to use.”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

> “Inject 15 mL of DARZALEX FASPRO into the subcutaneous tissue of the 
> abdomen approximately 3 inches [7.5 cm] to the right or left of the navel 
> over approximately 3 to 5 minutes. No data are available on performing 
> the injection at other sites of the body.
> •	 Rotate injection sites for successive injections.
> •	 Never inject DARZALEX FASPRO into areas where the skin is red, bruised, 
> tender, hard or areas where there are scars.
> •	 Pause or slow down delivery rate if the patient experiences pain. In the 
> event pain is not alleviated by pausing or slowing down delivery rate, a 
> second injection site may be chosen on the opposite side of the abdomen 
> to deliver the remainder of the dose.
> •	 During treatment with DARZALEX  FASPRO, do not administer other 
> medications for subcutaneous use at the same site as DARZALEX FASPRO.”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

<a id="darzalex-faspro-storage"></a>

### How should Darzalex Faspro be stored before injection?

> “Remove the DARZALEX FASPRO vial from refrigerated storage [2°C to 8°C 
> (36°F to 46°F)] and equilibrate to ambient temperature [15°C to 30°C (59°F 
> to 86°F)]. Store the unpunctured vial at ambient temperature and ambient 
> light for a maximum of 24 hours. Keep out of direct sunlight. Do not shake.”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

> “If the syringe containing DARZALEX FASPRO is not used immediately, store 
> refrigerated at 2°C to 8°C (36°F to 46°F) for up to 24 hours and/or at room 
> temperature at 15°C to 25°C (59°F to 77°F) for up to 12 hours under ambient light.
> •	 Discard if storage time exceeds these limits.
> •	 If stored in the refrigerator, allow the solution to come to room temperature 
> before administration.”

Source: [DARZALEX: DARZALEX FASPRO®, page 4, captured 2026-11-12](https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf#page=4)

## Related pages
- [Medical information: Darzalex (daratumumab): Multiple myeloma](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma)
- [Indication](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/safety)
- [Drug interactions](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/drug-interactions)
- [Storage and supply](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/storage-and-supply)
- [Guidelines](https://www.evicenter.com/medical-information/darzalex--multiple-myeloma/guidelines)
